Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antiulcer, benzimidazole derivatives	4162	138530-94-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexlansoprazole sesquihydrate R-Lansoprazole (R)-Lansoprazole dexlansoprazole kapidex dexilant TAK-390 TAK-390MR	Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production. Molecular weight: 369.36 Formula: C16H14F3N3O2S CLOGP: 2.79 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 67.87 ALOGS: -3.17 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexlansoprazole sesquihydrate
R-Lansoprazole
(R)-Lansoprazole
dexlansoprazole
kapidex
dexilant
TAK-390
TAK-390MR

Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.

Molecular weight: 369.36
Formula: C16H14F3N3O2S
CLOGP: 2.79
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 67.87
ALOGS: -3.17
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.21 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ZAP70	50
kinase-selectivity-class	AXL	1
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	4.436		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	1
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		Moderate	0.73
rat-kpuu-brain	Rat brain Kpuu	0.216	%	High	1

Approvals:

Date	Agency	Company	Orphan
Jan. 30, 2009	FDA	TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	789.19	12.25	429	47954	49762	90530302
Tenosynovitis	258.25	12.25	135	48248	14432	90565632
End stage renal disease	247.65	12.25	111	48272	8460	90571604
Renal injury	225.75	12.25	110	48273	10133	90569931
Enthesopathy	201.29	12.25	99	48284	9305	90570759
Blood pressure systolic increased	195.94	12.25	196	48187	58149	90521915
Tongue disorder	182.16	12.25	97	48286	10763	90569301
Rheumatoid nodule	173.02	12.25	117	48266	20049	90560015
Sputum discoloured	169.47	12.25	116	48267	20275	90559789
Bronchopulmonary aspergillosis allergic	162.99	12.25	65	48318	3701	90576363
Ulcer	154.02	12.25	133	48250	32749	90547315
Blood parathyroid hormone decreased	150.19	12.25	89	48294	12127	90567937
Tendonitis	148.51	12.25	109	48274	21263	90558801
Red blood cell sedimentation rate	146.39	12.25	64	48319	4594	90575470
Total lung capacity decreased	145.36	12.25	60	48323	3735	90576329
Lung opacity	141.92	12.25	68	48315	6034	90574030
Panniculitis	141.31	12.25	91	48292	14367	90565697
Maternal exposure during pregnancy	136.77	12.25	16	48367	360047	90220017
Blood calcium increased	130.61	12.25	81	48302	11977	90568087
Pemphigus	128.01	12.25	13	48370	326851	90253213
Granuloma skin	126.59	12.25	76	48307	10604	90569460
Incorrect product administration duration	126.31	12.25	95	48288	19227	90560837
Skin necrosis	125.90	12.25	90	48293	16851	90563213
Skin ulcer	125.36	12.25	144	48239	49931	90530133
Pleuritic pain	120.27	12.25	73	48310	10388	90569676
Obstructive airways disorder	117.85	12.25	103	48280	25766	90554298
Blood test abnormal	115.23	12.25	93	48290	20859	90559205
Glossodynia	104.80	12.25	22	48361	321757	90258307
Exposure during pregnancy	103.10	12.25	6	48377	238404	90341660
Alanine aminotransferase abnormal	101.08	12.25	52	48331	5374	90574690
Fear of injection	99.39	12.25	60	48323	8455	90571609
Cough	95.51	12.25	420	47963	368542	90211522
Hypercalcaemia	86.59	12.25	99	48284	34141	90545923
Aspiration	84.90	12.25	69	48314	15624	90564440
Pericarditis	84.87	12.25	20	48363	270131	90309933
Rales	82.29	12.25	68	48315	15759	90564305
Rash pruritic	82.07	12.25	153	48230	82061	90498003
Basal cell carcinoma	81.85	12.25	95	48288	33294	90546770
Body temperature decreased	81.75	12.25	81	48302	23735	90556329
Muscle injury	77.75	12.25	4	48379	176650	90403414
Blood pressure fluctuation	75.60	12.25	115	48268	52298	90527766
Helicobacter infection	74.89	12.25	15	48368	226835	90353229
Drug eruption	74.14	12.25	93	48290	35314	90544750
Hepatic enzyme increased	74.03	12.25	51	48332	360685	90219379
Allergy to chemicals	72.90	12.25	37	48346	3717	90576347
Duodenal ulcer perforation	72.29	12.25	15	48368	221273	90358791
Systemic lupus erythematosus	69.30	12.25	55	48328	361841	90218223
Joint injury	67.13	12.25	85	48298	32579	90547485
Wound	66.02	12.25	40	48343	302940	90277124
Forced expiratory volume decreased	65.41	12.25	40	48343	5768	90574296
Endometriosis	65.22	12.25	41	48342	6207	90573857
Hand deformity	64.75	12.25	39	48344	296323	90283741
Rheumatoid factor positive	64.20	12.25	8	48375	171642	90408422
Bronchiectasis	64.11	12.25	69	48314	22261	90557803
Rebound acid hypersecretion	63.91	12.25	18	48365	342	90579722
Faeces soft	63.04	12.25	43	48340	7468	90572596
Folliculitis	62.47	12.25	16	48367	204337	90375727
Haemoptysis	61.14	12.25	82	48301	33238	90546826
Impaired healing	59.89	12.25	25	48358	234174	90345890
Arthritis	59.85	12.25	211	48172	167104	90412960
Blood creatinine increased	59.18	12.25	152	48231	101234	90478830
Peak expiratory flow rate decreased	57.64	12.25	19	48364	623	90579441
Crepitations	56.69	12.25	43	48340	8809	90571255
Confusional state	56.53	12.25	74	48309	386131	90193933
Erythema	55.50	12.25	256	48127	228990	90351074
Antinuclear antibody positive	55.05	12.25	43	48340	9198	90570866
Type 2 diabetes mellitus	54.76	12.25	20	48363	203224	90376840
Pulmonary mass	54.63	12.25	72	48311	28700	90551364
Swelling	53.80	12.25	88	48295	418970	90161094
Completed suicide	53.67	12.25	7	48376	145051	90435013
Synovial fluid analysis	52.47	12.25	27	48356	2791	90577273
Blood pressure diastolic decreased	52.28	12.25	68	48315	26758	90553306
Tenosynovitis stenosans	51.75	12.25	30	48353	3923	90576141
Asthma	51.12	12.25	260	48123	241900	90338164
Granuloma	50.94	12.25	35	48348	6150	90573914
Thrombocytopenia	50.66	12.25	24	48359	208701	90371363
Somatic delusion	50.46	12.25	17	48366	597	90579467
Upper respiratory tract infection	50.42	12.25	167	48216	128151	90451913
Drug interaction	49.25	12.25	45	48338	276408	90303656
Irritable bowel syndrome	48.62	12.25	25	48358	207423	90372641
Cervix neoplasm	48.54	12.25	13	48370	203	90579861
Blister	48.48	12.25	39	48344	254959	90325105
Toxicity to various agents	47.64	12.25	50	48333	287796	90292268
Headache	47.60	12.25	684	47699	862062	89718002
Injury	47.42	12.25	23	48360	197326	90382738
Defaecation disorder	47.15	12.25	18	48365	911	90579153
Drug specific antibody	46.58	12.25	24	48359	2488	90577576
Scleritis	46.54	12.25	31	48352	5177	90574887
Transaminases increased	45.90	12.25	76	48307	37116	90542948
Arteriovenous fistula occlusion	45.82	12.25	14	48369	357	90579707
Heart rate decreased	45.39	12.25	93	48290	53412	90526652
Stomatitis	45.14	12.25	48	48335	274650	90305414
Gastric disorder	44.99	12.25	71	48312	33313	90546751
Extra dose administered	44.97	12.25	38	48345	9080	90570984
Rhinorrhoea	44.09	12.25	125	48258	88191	90491873
Echocardiogram abnormal	43.94	12.25	20	48363	1579	90578485
Gut fermentation syndrome	43.51	12.25	8	48375	16	90580048
Abdominal pain	43.38	12.25	360	48023	395361	90184703
Lip dry	42.26	12.25	3	48380	100952	90479112
Blue toe syndrome	42.10	12.25	14	48369	472	90579592
Sleep disorder due to general medical condition, insomnia type	41.45	12.25	9	48374	128685	90451379
Frustration tolerance decreased	41.20	12.25	34	48349	7862	90572202
Oropharyngeal pain	40.09	12.25	144	48239	115043	90465021
Chromaturia	39.53	12.25	50	48333	19137	90560927
Musculoskeletal disorder	39.06	12.25	53	48330	21716	90558348
Blood pressure diastolic abnormal	38.12	12.25	50	48333	19831	90560233
Blood cholesterol increased	38.07	12.25	33	48350	207979	90372085
Analgesic therapy	37.66	12.25	14	48369	658	90579406
Inflammation	37.14	12.25	191	48192	178401	90401663
Aphonia	37.01	12.25	39	48344	12280	90567784
Aspartate aminotransferase increased	36.95	12.25	130	48253	102807	90477257
Gout	36.44	12.25	45	48338	16814	90563250
Antacid therapy	36.09	12.25	14	48369	740	90579324
Renal failure	36.00	12.25	152	48231	130855	90449209
Appendicolith	35.97	12.25	14	48369	747	90579317
Poor venous access	35.74	12.25	48	48335	19479	90560585
Rheumatoid lung	35.65	12.25	24	48359	4079	90575985
Drug therapy	35.14	12.25	14	48369	795	90579269
Neutropenia	35.08	12.25	41	48342	224863	90355201
Heart rate increased	35.00	12.25	136	48247	112766	90467298
Anticoagulant therapy	35.00	12.25	14	48369	803	90579261
Delirium	34.22	12.25	7	48376	104352	90475712
Central obesity	33.88	12.25	16	48367	1374	90578690
Peripheral venous disease	33.71	12.25	3	48380	83918	90496146
Total lung capacity increased	33.51	12.25	25	48358	4996	90575068
Cushingoid	33.19	12.25	34	48349	10361	90569703
Drug abuse	32.93	12.25	3	48380	82344	90497720
No adverse event	32.74	12.25	95	48288	67887	90512177
Gait inability	32.35	12.25	19	48364	146437	90433627
Dysphonia	32.18	12.25	90	48293	62994	90517070
Thrombosis	32.10	12.25	99	48284	73152	90506912
Musculoskeletal stiffness	32.05	12.25	269	48114	296263	90283801
Loss of personal independence in daily activities	31.45	12.25	150	48233	135955	90444109
Synovial disorder	31.39	12.25	20	48363	3098	90576966
Lung diffusion test decreased	31.36	12.25	13	48370	818	90579246
Blood pressure systolic decreased	30.84	12.25	31	48352	9239	90570825
Deformity	30.45	12.25	35	48348	12135	90567929
Pulmonary toxicity	30.27	12.25	34	48349	11497	90568567
Disease progression	29.69	12.25	24	48359	156591	90423473
Nasal congestion	29.64	12.25	105	48278	83309	90496755
Wound infection	29.46	12.25	10	48373	106392	90473672
Pulmonary thrombosis	29.44	12.25	31	48352	9751	90570313
Pneumococcal infection	29.33	12.25	14	48369	1231	90578833
Pharyngitis streptococcal	29.14	12.25	35	48348	12707	90567357
Synovial cyst	28.07	12.25	33	48350	11719	90568345
Bone density decreased	27.80	12.25	40	48343	17305	90562759
Liver injury	27.79	12.25	30	48353	170537	90409527
Tubulointerstitial nephritis	27.60	12.25	49	48334	25294	90554770
Respiration abnormal	27.17	12.25	27	48356	7936	90572128
Grip strength decreased	26.87	12.25	8	48375	92568	90487496
Gastrooesophageal reflux disease	26.71	12.25	166	48217	166171	90413893
Red blood cell count decreased	26.52	12.25	69	48314	46282	90533782
Productive cough	26.52	12.25	96	48287	76967	90503097
Serum amyloid A protein increased	26.32	12.25	11	48372	706	90579358
Therapeutic reaction time decreased	26.18	12.25	19	48364	3639	90576425
Hypoaldosteronism	25.84	12.25	9	48374	350	90579714
Depressed level of consciousness	25.78	12.25	4	48379	72780	90507284
Hypercholesterolaemia	25.41	12.25	11	48372	100881	90479183
Red blood cell sedimentation rate decreased	25.35	12.25	12	48371	1036	90579028
Joint effusion	25.30	12.25	41	48342	19669	90560395
Gastrointestinal motility disorder	25.25	12.25	23	48360	6068	90573996
Connective tissue inflammation	25.23	12.25	6	48377	56	90580008
Drug specific antibody present	25.20	12.25	22	48361	5492	90574572
Alanine aminotransferase increased	24.90	12.25	127	48256	118211	90461853
Bradycardia	24.79	12.25	7	48376	83840	90496224
Injection site oedema	24.74	12.25	14	48369	1749	90578315
Conjunctival haemorrhage	24.74	12.25	19	48364	3965	90576099
Impaired work ability	24.53	12.25	40	48343	19286	90560778
Renal pain	24.09	12.25	25	48358	7734	90572330
Thoracic operation	24.06	12.25	7	48376	150	90579914
Forced vital capacity decreased	24.02	12.25	12	48371	1166	90578898
Heart rate irregular	24.00	12.25	45	48338	24223	90555841
Feeling jittery	23.98	12.25	35	48348	15336	90564728
Urine odour abnormal	23.68	12.25	24	48359	7220	90572844
Hypertensive nephropathy	23.55	12.25	10	48373	668	90579396
Abnormal faeces	23.44	12.25	23	48360	6659	90573405
Parotid gland enlargement	23.43	12.25	11	48372	932	90579132
Discomfort	23.39	12.25	72	48311	274263	90305801
Hepatic enzyme decreased	23.27	12.25	11	48372	947	90579117
Acute kidney injury	23.04	12.25	267	48116	320120	90259944
Blood pressure increased	22.96	12.25	182	48201	197035	90383029
Tremor	22.82	12.25	150	48233	153023	90427041
Ill-defined disorder	22.61	12.25	40	48343	184851	90395213
Flail chest	22.57	12.25	6	48377	91	90579973
Patella fracture	22.39	12.25	15	48368	2528	90577536
Blood immunoglobulin E decreased	22.32	12.25	7	48376	195	90579869
Renal haemangioma	22.30	12.25	5	48378	35	90580029
Hyponatraemia	22.30	12.25	23	48360	133515	90446549
Oedema	22.17	12.25	46	48337	200249	90379815
Lung perforation	22.15	12.25	6	48377	98	90579966
Alopecia	22.14	12.25	164	48219	494907	90085157
Neoplasm malignant	22.08	12.25	53	48330	33827	90546237
Bladder disorder	22.08	12.25	28	48355	10744	90569320
Flank pain	22.02	12.25	38	48345	19184	90560880
Osteomyelitis	21.98	12.25	47	48336	27799	90552265
Peak expiratory flow rate abnormal	21.87	12.25	6	48377	103	90579961
Heart rate abnormal	21.78	12.25	21	48362	5950	90574114
Cardiac arrest	21.27	12.25	15	48368	104920	90475144
Fatigue	20.86	12.25	782	47601	1153241	89426823
Parapsoriasis	20.78	12.25	6	48377	125	90579939
Hyperaesthesia	20.65	12.25	27	48356	10675	90569389
Diarrhoea	20.62	12.25	651	47732	938539	89641525
Adjustment disorder with depressed mood	20.37	12.25	3	48380	56750	90523314
Drug tolerance	19.98	12.25	35	48348	17881	90562183
Skin irritation	19.82	12.25	30	48353	13573	90566491
Coma	19.80	12.25	7	48376	72625	90507439
Regurgitation	19.61	12.25	13	48370	2153	90577911
Injection site extravasation	19.37	12.25	24	48359	8995	90571069
Prescribed underdose	19.18	12.25	8	48375	75011	90505053
Epilepsy	19.11	12.25	10	48373	82196	90497868
Respiratory failure	19.09	12.25	21	48362	118397	90461667
Ocular hyperaemia	19.02	12.25	50	48333	33748	90546316
Aortic stenosis	18.93	12.25	20	48363	6316	90573748
Gastritis fungal	18.87	12.25	6	48377	175	90579889
Nodule	18.76	12.25	43	48340	26643	90553421
Facet joint syndrome	18.74	12.25	15	48368	98374	90481690
Eye pain	18.71	12.25	59	48324	44109	90535955
Pancytopenia	18.66	12.25	22	48361	120241	90459823
Drug tolerance decreased	18.56	12.25	48	48335	32082	90547982
Brain hypoxia	18.47	12.25	8	48375	561	90579503
Dry throat	18.43	12.25	22	48361	7938	90572126
Autoimmune disorder	18.34	12.25	9	48374	76735	90503329
Malignant neoplasm progression	18.30	12.25	18	48365	106852	90473212
Platelet count decreased	18.27	12.25	28	48355	136941	90443123
Electrocardiogram QT prolonged	18.08	12.25	8	48375	72448	90507616
Photophobia	18.07	12.25	37	48346	21232	90558832
Knee arthroplasty	18.07	12.25	11	48372	83171	90496893
Oral discomfort	18.02	12.25	25	48358	10458	90569606
Multiple organ dysfunction syndrome	17.94	12.25	7	48376	68329	90511735
Suicide attempt	17.78	12.25	9	48374	75390	90504674
Neutrophil count decreased	17.69	12.25	8	48375	71524	90508540
Feeling abnormal	17.67	12.25	151	48232	167084	90412980
Conjunctivitis	17.64	12.25	42	48341	26664	90553400
Hypoxia	17.60	12.25	81	48302	72318	90507746
Sleep disorder	17.57	12.25	51	48332	197979	90382085
Product dose omission issue	17.49	12.25	235	48148	291452	90288612
Pleural effusion	17.49	12.25	111	48272	111880	90468184
Pneumonia	17.49	12.25	455	47928	637604	89942460
Arthralgia	17.42	12.25	541	47842	777981	89802083
Peripheral swelling	17.22	12.25	313	48070	412793	90167271
Carcinoid tumour	17.20	12.25	7	48376	420	90579644
Eye haemorrhage	17.08	12.25	24	48359	10156	90569908
Abortion spontaneous	16.96	12.25	4	48379	54052	90526012
Nocturia	16.95	12.25	24	48359	10231	90569833
Eye irritation	16.86	12.25	48	48335	33930	90546134
White coat hypertension	16.75	12.25	9	48374	1016	90579048
Lung diffusion disorder	16.69	12.25	5	48378	119	90579945
Weight decreased	16.59	12.25	290	48093	379620	90200444
Arthropathy	16.51	12.25	121	48262	366121	90213943
Mononeuropathy	16.46	12.25	5	48378	125	90579939
Contraindicated product administered	16.31	12.25	102	48281	320037	90260027
Pain in extremity	16.28	12.25	334	48049	450195	90129869
AST/ALT ratio abnormal	16.27	12.25	5	48378	130	90579934
Stress	16.18	12.25	86	48297	81309	90498755
Contusion	16.15	12.25	74	48309	251142	90328922
Death	16.04	12.25	161	48222	456390	90123674
Hyperchlorhydria	16.02	12.25	11	48372	1930	90578134
Undifferentiated connective tissue disease	15.88	12.25	5	48378	141	90579923
Skin cancer	15.84	12.25	27	48356	13492	90566572
Drug-induced liver injury	15.71	12.25	15	48368	90303	90489761
Knee deformity	15.68	12.25	10	48373	1552	90578512
Obesity	15.63	12.25	20	48363	105487	90474577
Back injury	15.55	12.25	3	48380	46619	90533445
Mobility decreased	15.45	12.25	75	48308	250659	90329405
Blood pressure diastolic increased	15.42	12.25	26	48357	12880	90567184
Urinary tract disorder	15.36	12.25	14	48369	3697	90576367
Hyperphosphataemia	15.36	12.25	14	48369	3697	90576367
Lactic acidosis	15.32	12.25	4	48379	50459	90529605
Gastrointestinal disorder	15.12	12.25	78	48305	256609	90323455
Iodine allergy	15.10	12.25	8	48375	878	90579186
Groin infection	15.07	12.25	7	48376	579	90579485
Muscle strain	15.03	12.25	22	48361	9665	90570399
Myalgia	14.92	12.25	151	48232	174974	90405090
Influenza	14.84	12.25	126	48257	139138	90440926
Lupus vulgaris	14.82	12.25	3	48380	45056	90535008
Nausea	14.77	12.25	729	47654	1109587	89470477
Keratomileusis	14.70	12.25	5	48378	181	90579883
Amnesia	14.64	12.25	22	48361	108483	90471581
Foot fracture	14.60	12.25	39	48344	26567	90553497
Hypokalaemia	14.60	12.25	30	48353	131086	90448978
Bronchitis	14.57	12.25	135	48248	152792	90427272
Cardio-respiratory arrest	14.21	12.25	8	48375	63132	90516932
Skin sensitisation	14.08	12.25	8	48375	1007	90579057
Hip arthroplasty	14.04	12.25	12	48371	76196	90503868
Hypoprothrombinaemia	14.02	12.25	6	48377	409	90579655
Cardiac failure	14.02	12.25	23	48360	109473	90470591
Humidity intolerance	13.95	12.25	6	48377	414	90579650
Musculoskeletal discomfort	13.85	12.25	33	48350	20958	90559106
Abdominal pain upper	13.83	12.25	252	48131	332422	90247642
Nephrogenic anaemia	13.67	12.25	11	48372	2455	90577609
Atelectasis	13.62	12.25	36	48347	24373	90555691
Eye ulcer	13.57	12.25	6	48377	442	90579622
Blood phosphorus increased	13.56	12.25	14	48369	4304	90575760
Pulmonary fibrosis	13.50	12.25	101	48282	107402	90472662
Mucosal inflammation	13.41	12.25	7	48376	57618	90522446
Pituitary tumour recurrent	13.40	12.25	4	48379	94	90579970
Tonsillitis fungal	13.38	12.25	3	48380	21	90580043
Energy increased	13.33	12.25	12	48371	3118	90576946
Abdominal distension	13.31	12.25	117	48266	130484	90449580
Klebsiella bacteraemia	13.19	12.25	11	48372	2581	90577483
Red blood cell sedimentation rate increased	12.98	12.25	82	48301	82513	90497551
Quality of life decreased	12.96	12.25	23	48360	11866	90568198
Nephropathy	12.94	12.25	20	48363	9215	90570849
Lupus-like syndrome	12.82	12.25	5	48378	48841	90531223
Spirometry abnormal	12.79	12.25	5	48378	270	90579794
Arthroscopic surgery	12.77	12.25	4	48379	111	90579953
Secretion discharge	12.74	12.25	27	48356	15869	90564195
Mental status changes	12.71	12.25	4	48379	44675	90535389
Hallucination	12.63	12.25	10	48373	65949	90514115
Liver function test increased	12.57	12.25	83	48300	84772	90495292
Drug hypersensitivity	12.51	12.25	330	48053	463279	90116785
Vomiting	12.47	12.25	323	48060	787970	89792094
Hepatic failure	12.35	12.25	3	48380	39725	90540339
Seizure	12.34	12.25	41	48342	152588	90427476
Night sweats	12.29	12.25	32	48351	128734	90451330
Rhabdomyolysis	12.26	12.25	6	48377	51250	90528814

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	353.82	19.04	250	22102	46991	42551992
End stage renal disease	297.99	19.04	154	22198	16404	42582579
Hyperphosphataemia	197.38	19.04	108	22244	12896	42586087
Myasthenia gravis	185.98	19.04	112	22240	16025	42582958
Sleep disorder therapy	174.60	19.04	81	22271	6813	42592170
Analgesic therapy	169.43	19.04	78	22274	6446	42592537
Synovitis	166.47	19.04	103	22249	15464	42583519
Appendicolith	161.83	19.04	96	22256	13360	42585623
Blood phosphorus increased	160.22	19.04	93	22259	12432	42586551
Drug therapy	146.30	19.04	70	22282	6310	42592673
Ulcer	144.15	19.04	96	22256	16345	42582638
Stress	142.50	19.04	144	22208	44068	42554915
Incorrect route of product administration	142.20	19.04	111	22241	24194	42574789
Neuralgia	139.05	19.04	112	22240	25535	42573448
Tenosynovitis	137.34	19.04	61	22291	4634	42594349
Blood uric acid increased	134.43	19.04	90	22262	15457	42583526
Hypophosphataemia	134.25	19.04	101	22251	20844	42578139
Drug intolerance	132.64	19.04	186	22166	80238	42518745
Enthesopathy	132.53	19.04	60	22292	4768	42594215
Appendicitis	131.23	19.04	99	22253	20514	42578469
Iron deficiency	125.44	19.04	76	22276	10985	42587998
Renal injury	123.10	19.04	78	22274	12202	42586781
Psoriatic arthropathy	122.72	19.04	103	22249	24864	42574119
Ventricular fibrillation	121.42	19.04	111	22241	30012	42568971
C-reactive protein abnormal	119.06	19.04	69	22283	9192	42589791
Bacterial infection	116.81	19.04	105	22247	27774	42571209
Abdominal distension	109.58	19.04	160	22192	71575	42527408
Tongue disorder	108.25	19.04	54	22298	5329	42593654
Anticoagulant therapy	107.77	19.04	51	22301	4484	42594499
Terminal insomnia	106.98	19.04	33	22319	886	42598097
Antacid therapy	105.86	19.04	51	22301	4666	42594317
Drug hypersensitivity	104.43	19.04	187	22165	99202	42499781
Blood cholesterol increased	102.84	19.04	96	22256	26645	42572338
Alanine aminotransferase abnormal	100.61	19.04	50	22302	4894	42594089
Activated partial thromboplastin time prolonged	98.17	19.04	75	22277	15828	42583155
Drug interaction	96.49	19.04	13	22339	266986	42331997
Chronic obstructive pulmonary disease	90.95	19.04	137	22215	62977	42536006
Dry mouth	90.39	19.04	108	22244	39771	42559212
Swelling	81.73	19.04	121	22231	54764	42544219
Tendonitis	80.09	19.04	55	22297	9839	42589144
Blood test abnormal	77.76	19.04	60	22292	12846	42586137
Micturition urgency	75.39	19.04	57	22295	11841	42587142
Diabetes mellitus	73.49	19.04	121	22231	59966	42539017
Blood calcium increased	73.21	19.04	49	22303	8405	42590578
Bronchopulmonary aspergillosis allergic	71.99	19.04	39	22313	4559	42594424
Cardiogenic shock	70.27	19.04	90	22262	35550	42563433
Asthma	70.25	19.04	121	22231	62193	42536790
Injection site warmth	69.40	19.04	32	22320	2651	42596332
Congenital hiatus hernia	68.91	19.04	42	22310	6132	42592851
Incorrect product administration duration	68.20	19.04	41	22311	5839	42593144
Hyperlipidaemia	67.30	19.04	69	22283	21447	42577536
Red blood cell sedimentation rate	66.50	19.04	24	22328	1056	42597927
Thrombocytopenia	64.71	19.04	11	22341	190268	42408715
Granuloma skin	64.52	19.04	24	22328	1151	42597832
Sleep disorder	64.48	19.04	101	22251	47994	42550989
Pelvic pain	63.53	19.04	32	22320	3222	42595761
Thrombosis	60.80	19.04	120	22232	68391	42530592
Device dislocation	59.79	19.04	42	22310	7789	42591194
Pleuritic pain	58.84	19.04	40	22312	7037	42591946
Lower respiratory tract infection	58.69	19.04	89	22263	41117	42557866
Aortic stenosis	57.86	19.04	43	22309	8702	42590281
Blood parathyroid hormone decreased	56.72	19.04	24	22328	1619	42597364
Mobility decreased	55.67	19.04	80	22272	35226	42563757
General physical health deterioration	54.69	19.04	189	22163	151057	42447926
Troponin increased	54.02	19.04	58	22294	19004	42579979
Full blood count abnormal	53.54	19.04	72	22280	29804	42569179
Intentional product misuse	53.21	19.04	107	22245	61793	42537190
Gout	52.41	19.04	69	22283	27986	42570997
Ascites	51.16	19.04	100	22252	56578	42542405
Device malfunction	50.77	19.04	46	22306	12281	42586702
Panniculitis	50.21	19.04	24	22328	2157	42596826
Injection site mass	49.77	19.04	39	22313	8536	42590447
Joint injury	47.59	19.04	48	22304	14628	42584355
Occupational dermatitis	47.22	19.04	11	22341	95	42598888
Total lung capacity decreased	46.94	19.04	27	22325	3543	42595440
Inspiratory capacity abnormal	46.82	19.04	11	22341	99	42598884
Kidney infection	46.39	19.04	34	22318	6736	42592247
Rheumatoid nodule	45.77	19.04	25	22327	2970	42596013
Abdominal pain	45.46	19.04	209	22143	190262	42408721
Oral herpes	45.28	19.04	35	22317	7509	42591474
Toxicity to various agents	44.69	19.04	33	22319	229103	42369880
Stiff person syndrome	44.52	19.04	12	22340	196	42598787
Musculoskeletal stiffness	43.97	19.04	95	22257	57670	42541313
Bacteroides infection	43.47	19.04	23	22329	2564	42596419
Drug abuse	43.28	19.04	3	22349	104768	42494215
Neck pain	42.98	19.04	65	22287	29949	42569034
Occupational exposure to air contaminants	41.93	19.04	11	22341	161	42598822
Oesophageal polyp	41.50	19.04	9	22343	54	42598929
Nerve degeneration	40.02	19.04	11	22341	194	42598789
Neutropenia	39.82	19.04	28	22324	199403	42399580
Loss of personal independence in daily activities	39.14	19.04	83	22269	49733	42549250
Headache	38.79	19.04	236	22116	239133	42359850
Lung opacity	37.05	19.04	28	22324	5809	42593174
Disease progression	36.21	19.04	15	22337	143641	42455342
Respiratory failure	34.59	19.04	12	22340	128120	42470863
Orthostatic hypertension	34.58	19.04	12	22340	470	42598513
Hyponatraemia	34.23	19.04	124	22228	101338	42497645
Tender joint count decreased	32.72	19.04	10	22342	260	42598723
Swollen joint count decreased	32.72	19.04	10	22342	260	42598723
Sputum discoloured	32.60	19.04	33	22319	10099	42588884
Somnolence	32.28	19.04	153	22199	140952	42458031
Benign prostatic hyperplasia	32.15	19.04	47	22305	21005	42577978
Dry eye	31.88	19.04	40	22312	15466	42583517
Pancytopenia	31.83	19.04	11	22341	117732	42481251
Bone hypertrophy	31.61	19.04	10	22342	292	42598691
Multiple organ dysfunction syndrome	31.39	19.04	117	22235	96918	42502065
Seizure	31.34	19.04	12	22340	120549	42478434
Therapeutic response shortened	31.17	19.04	37	22315	13517	42585466
Respiratory symptom	30.08	19.04	33	22319	11073	42587910
Cardiovascular disorder	29.94	19.04	36	22316	13329	42585654
Breath sounds abnormal	29.45	19.04	34	22318	12059	42586924
Blood immunoglobulin E increased	28.98	19.04	20	22332	3605	42595378
Aspiration	28.88	19.04	41	22311	17845	42581138
Aspartate aminotransferase increased	28.34	19.04	97	22255	77066	42521917
Cardiac arrest	28.22	19.04	11	22341	109309	42489674
SAPHO syndrome	28.17	19.04	10	22342	419	42598564
Ocular hyperaemia	27.88	19.04	38	22314	15925	42583058
Nephrogenic anaemia	27.35	19.04	17	22335	2569	42596414
Platelet count decreased	26.93	19.04	20	22332	138561	42460422
Skin necrosis	26.86	19.04	24	22328	6290	42592693
Injection site reaction	26.81	19.04	37	22315	15684	42583299
Hypercholesterolaemia	26.18	19.04	33	22319	12816	42586167
Leukopenia	26.10	19.04	4	22348	74742	42524241
Condition aggravated	26.01	19.04	229	22123	260525	42338458
Drug tolerance	25.94	19.04	18	22334	3272	42595711
Treatment failure	25.93	19.04	82	22270	62542	42536441
Feeling hot	25.65	19.04	45	22307	23437	42575546
Pyrexia	25.64	19.04	113	22239	393929	42205054
Pain	25.44	19.04	217	22135	244631	42354352
Injection site erythema	25.11	19.04	41	22311	20154	42578829
Constipation	24.98	19.04	158	22194	162133	42436850
Atrial fibrillation	24.82	19.04	22	22330	139571	42459412
Renal haemangioma	24.73	19.04	5	22347	20	42598963
Haemoglobin decreased	24.62	19.04	20	22332	132451	42466532
Hyperkalaemia	22.65	19.04	7	22345	80451	42518532
Burning sensation	22.61	19.04	40	22312	20973	42578010
Renal neoplasm	21.68	19.04	12	22340	1463	42597520
Erythema of eyelid	21.47	19.04	12	22340	1491	42597492
Dehydration	21.08	19.04	26	22326	141741	42457242
Sensory disturbance	21.01	19.04	22	22330	7001	42591982
Renal mass	20.76	19.04	13	22339	1989	42596994
Occupational exposure to product	20.65	19.04	8	22344	429	42598554
Fatigue	20.42	19.04	331	22021	435310	42163673
Serum amyloid A protein increased	20.40	19.04	7	22345	265	42598718
Restrictive pulmonary disease	19.79	19.04	11	22341	1352	42597631
Syncope	19.76	19.04	14	22338	99392	42499591
Hypertensive nephropathy	19.62	19.04	8	22344	491	42598492
Bone density decreased	19.61	19.04	13	22339	2193	42596790

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	555.18	13.36	410	62506	75881	110450502
Tenosynovitis	396.53	13.36	191	62725	16092	110510291
End stage renal disease	349.38	13.36	192	62724	21281	110505102
Enthesopathy	330.21	13.36	155	62761	12323	110514060
Tongue disorder	292.56	13.36	149	62767	14149	110512234
Ulcer	287.46	13.36	220	62696	42896	110483487
Tendonitis	235.47	13.36	160	62756	25923	110500460
Bronchopulmonary aspergillosis allergic	233.28	13.36	108	62808	8318	110518065
Rheumatoid nodule	223.51	13.36	141	62775	20155	110506228
Blood calcium increased	220.67	13.36	134	62782	17906	110508477
Red blood cell sedimentation rate	209.96	13.36	87	62829	5127	110521256
Blood test abnormal	208.77	13.36	154	62762	28400	110497983
Hyperphosphataemia	203.77	13.36	123	62793	16258	110510125
Sputum discoloured	202.70	13.36	150	62766	27795	110498588
Analgesic therapy	200.52	13.36	93	62823	7191	110519192
Blood parathyroid hormone decreased	199.14	13.36	112	62804	12977	110513406
Alanine aminotransferase abnormal	198.93	13.36	100	62816	9234	110517149
Total lung capacity decreased	196.37	13.36	91	62825	7023	110519360
Appendicolith	187.62	13.36	111	62805	14144	110512239
Panniculitis	186.12	13.36	114	62802	15468	110510915
Pleuritic pain	184.95	13.36	115	62801	16025	110510358
Sleep disorder therapy	179.95	13.36	87	62829	7384	110518999
Granuloma skin	178.34	13.36	99	62817	11184	110515199
Drug therapy	175.90	13.36	85	62831	7206	110519177
Lung opacity	175.36	13.36	99	62817	11553	110514830
Blood pressure systolic increased	173.78	13.36	225	62691	82766	110443617
Myasthenia gravis	168.57	13.36	121	62795	21390	110504993
Blood phosphorus increased	166.25	13.36	108	62808	16232	110510151
Skin necrosis	150.50	13.36	113	62803	21399	110504984
Drug interaction	144.61	13.36	52	62864	500131	110026252
Blood uric acid increased	137.24	13.36	107	62809	21422	110504961
Anticoagulant therapy	136.93	13.36	65	62851	5296	110521087
Antacid therapy	135.53	13.36	65	62851	5419	110520964
Toxicity to various agents	133.83	13.36	53	62863	480502	110045881
Skin ulcer	132.37	13.36	172	62744	63473	110462910
Appendicitis	126.71	13.36	115	62801	28349	110498034
Renal injury	121.44	13.36	94	62822	18619	110507764
Stress	118.49	13.36	214	62702	105134	110421249
Joint injury	117.67	13.36	129	62787	39865	110486518
Aspiration	114.18	13.36	112	62804	30421	110495962
Fear of injection	108.48	13.36	66	62850	8845	110517538
Thrombocytopenia	108.31	13.36	32	62884	348853	110177530
Hypophosphataemia	108.15	13.36	113	62803	33069	110493314
Asthma	106.60	13.36	349	62567	249942	110276441
Neuralgia	105.49	13.36	134	62782	48344	110478039
Iron deficiency	105.32	13.36	86	62830	18390	110507993
Thrombosis	105.15	13.36	207	62709	108455	110417928
Bacterial infection	104.55	13.36	130	62786	45906	110480477
Maternal exposure during pregnancy	103.25	13.36	12	62904	254871	110271512
Basal cell carcinoma	98.30	13.36	125	62791	45145	110481238
Gout	97.41	13.36	112	62804	36454	110489929
Activated partial thromboplastin time prolonged	96.88	13.36	89	62827	22279	110504104
Ventricular fibrillation	94.36	13.36	117	62799	41196	110485187
Incorrect route of product administration	90.39	13.36	144	62772	63917	110462466
Terminal insomnia	87.13	13.36	35	62881	1903	110524480
Rash pruritic	84.42	13.36	178	62738	97891	110428492
Drug abuse	84.09	13.36	4	62912	177407	110348976
Obstructive airways disorder	82.67	13.36	116	62800	46033	110480350
Hypercalcaemia	81.68	13.36	116	62800	46541	110479842
Headache	80.78	13.36	811	62105	881566	109644817
Rales	80.18	13.36	84	62832	24655	110501728
Pemphigus	80.05	13.36	13	62903	214557	110311826
Aortic stenosis	79.13	13.36	63	62853	12996	110513387
Drug hypersensitivity	77.35	13.36	482	62434	453608	110072775
Abdominal pain	77.33	13.36	528	62388	512461	110013922
Chronic obstructive pulmonary disease	76.99	13.36	183	62733	108975	110417408
Abdominal distension	75.26	13.36	245	62671	174858	110351525
Bronchiectasis	73.34	13.36	97	62819	36396	110489987
Drug eruption	72.13	13.36	118	62798	53541	110472842
Allergy to chemicals	71.96	13.36	36	62880	3289	110523094
Upper respiratory tract infection	71.77	13.36	200	62716	131128	110395255
Cough	71.25	13.36	478	62438	461163	110065220
Endometriosis	71.16	13.36	39	62877	4295	110522088
Loss of personal independence in daily activities	70.98	13.36	217	62699	149803	110376580
Neutropenia	69.93	13.36	66	62850	374554	110151829
Musculoskeletal stiffness	68.53	13.36	328	62588	279494	110246889
Pericarditis	68.15	13.36	20	62896	219094	110307289
Aspartate aminotransferase increased	68.03	13.36	223	62693	159713	110366670
Congenital hiatus hernia	67.70	13.36	43	62873	6216	110520167
Hyperlipidaemia	67.04	13.36	92	62824	35756	110490627
Glossodynia	65.94	13.36	22	62894	221982	110304401
Muscle injury	64.17	13.36	4	62912	140803	110385580
Diabetes mellitus	64.11	13.36	161	62755	99220	110427163
Blood creatinine increased	63.95	13.36	239	62677	182650	110343733
Erythema	63.15	13.36	330	62586	291117	110235266
Confusional state	62.14	13.36	107	62809	468573	110057810
Helicobacter infection	59.57	13.36	15	62901	181862	110344521
Crepitations	58.76	13.36	49	62867	10786	110515597
Blister	58.59	13.36	28	62888	227348	110299035
Disease progression	58.51	13.36	33	62883	244001	110282382
Blood pressure diastolic decreased	58.12	13.36	86	62830	35799	110490584
Respiratory failure	57.85	13.36	25	62891	215307	110311076
Blood pressure fluctuation	56.65	13.36	129	62787	74695	110451688
Duodenal ulcer perforation	55.66	13.36	16	62900	177684	110348699
Faeces soft	55.28	13.36	48	62868	11162	110515221
Peak expiratory flow rate decreased	54.84	13.36	19	62897	681	110525702
Stomatitis	54.79	13.36	44	62872	270198	110256185
Cardiogenic shock	53.96	13.36	108	62808	57230	110469153
Body temperature decreased	53.44	13.36	84	62832	36851	110489532
Tenosynovitis stenosans	52.56	13.36	30	62886	3573	110522810
Drug intolerance	52.31	13.36	403	62513	406109	110120274
Synovial fluid analysis	52.12	13.36	27	62889	2654	110523729
Fatigue	51.67	13.36	974	61942	1214984	109311399
Rheumatoid factor positive	51.34	13.36	7	62909	131633	110394750
Micturition urgency	51.16	13.36	59	62857	19261	110507122
Cardiac arrest	51.04	13.36	24	62892	196729	110329654
Impaired healing	51.02	13.36	24	62892	196693	110329690
Type 2 diabetes mellitus	50.17	13.36	19	62897	177213	110349170
Rheumatoid lung	50.15	13.36	31	62885	4273	110522110
Rhinorrhoea	49.95	13.36	150	62766	102516	110423867
Ocular hyperaemia	49.59	13.36	84	62832	39202	110487181
Granuloma	49.57	13.36	42	62874	9448	110516935
Bone density decreased	49.37	13.36	53	62863	15989	110510394
Cervix neoplasm	49.17	13.36	13	62903	180	110526203
Rhabdomyolysis	47.92	13.36	6	62910	120395	110405988
Pancytopenia	47.91	13.36	30	62886	209583	110316800
Defaecation disorder	47.69	13.36	18	62898	827	110525556
Psoriatic arthropathy	47.68	13.36	230	62686	196531	110329852
Transaminases increased	47.67	13.36	109	62807	63281	110463102
Somatic delusion	46.73	13.36	17	62899	704	110525679
Occupational dermatitis	46.45	13.36	12	62904	151	110526232
Depressed level of consciousness	46.17	13.36	5	62911	112273	110414110
Systemic lupus erythematosus	46.06	13.36	46	62870	254292	110272091
Serum amyloid A protein increased	45.79	13.36	18	62898	924	110525459
Folliculitis	45.77	13.36	19	62897	167634	110358749
Inspiratory capacity abnormal	45.63	13.36	11	62905	102	110526281
Wound	45.27	13.36	40	62876	234397	110291986
Platelet count decreased	44.89	13.36	39	62877	230404	110295979
Completed suicide	44.86	13.36	43	62873	242338	110284045
Pulmonary mass	44.78	13.36	78	62838	37223	110489160
Blood pressure systolic decreased	44.20	13.36	46	62870	13395	110512988
Musculoskeletal disorder	43.64	13.36	59	62857	22605	110503778
C-reactive protein abnormal	43.27	13.36	167	62749	129528	110396855
Drug tolerance	42.83	13.36	50	62866	16535	110509848
Injury	42.44	13.36	24	62892	177241	110349142
Seizure	42.40	13.36	38	62878	221147	110305236
Neutrophil count decreased	41.53	13.36	9	62907	120932	110405451
Scleritis	41.34	13.36	30	62886	5390	110520993
Occupational exposure to air contaminants	41.04	13.36	11	62905	161	110526222
Arthritis	40.67	13.36	196	62720	167390	110358993
Hand deformity	40.16	13.36	39	62877	218467	110307916
Lip dry	39.80	13.36	5	62911	100078	110426305
Drug specific antibody	39.79	13.36	23	62893	2805	110523578
Arteriovenous fistula occlusion	39.55	13.36	14	62902	535	110525848
Liver injury	39.55	13.36	18	62898	150395	110375988
Pelvic pain	39.41	13.36	47	62869	15895	110510488
Heart rate decreased	39.40	13.36	120	62796	82636	110443747
Troponin increased	39.38	13.36	65	62851	29701	110496682
Hepatic function abnormal	39.33	13.36	3	62913	89292	110437091
Gut fermentation syndrome	39.33	13.36	8	62908	30	110526353
Bacteroides infection	39.12	13.36	23	62893	2896	110523487
Aphonia	38.72	13.36	42	62874	12818	110513565
Oropharyngeal pain	38.63	13.36	166	62750	135110	110391273
Hepatic enzyme increased	38.32	13.36	78	62838	320814	110205569
Irritable bowel syndrome	38.23	13.36	23	62893	164192	110362191
Coma	38.05	13.36	10	62906	117859	110408524
Full blood count abnormal	37.40	13.36	92	62824	55960	110470423
Delirium	37.35	13.36	15	62901	135010	110391373
Cardio-respiratory arrest	37.07	13.36	10	62906	115826	110410557
Injection site mass	37.03	13.36	57	62859	24556	110501827
Oesophageal polyp	36.63	13.36	9	62907	91	110526292
Gastric disorder	36.51	13.36	67	62849	33290	110493093
Blue toe syndrome	36.47	13.36	14	62902	674	110525709
Frustration tolerance decreased	36.37	13.36	34	62882	8697	110517686
Blood pressure diastolic abnormal	36.37	13.36	58	62858	25757	110500626
Forced expiratory volume decreased	36.17	13.36	41	62875	13135	110513248
Inflammation	35.93	13.36	210	62706	193028	110333355
Therapeutic response shortened	35.69	13.36	62	62854	29521	110496862
Deformity	35.63	13.36	36	62880	10124	110516259
Nerve degeneration	35.51	13.36	11	62905	275	110526108
Tender joint count decreased	35.11	13.36	11	62905	286	110526097
Gastrooesophageal reflux disease	35.04	13.36	198	62718	179778	110346605
Dry mouth	34.44	13.36	213	62703	199735	110326648
Rebound acid hypersecretion	34.43	13.36	9	62907	119	110526264
Kidney infection	34.00	13.36	56	62860	25543	110500840
Peripheral venous disease	33.94	13.36	4	62912	84113	110442270
Ascites	33.86	13.36	123	62793	92685	110433698
Dysphonia	33.28	13.36	107	62809	75822	110450561
Antinuclear antibody positive	33.10	13.36	33	62883	9135	110517248
Benign prostatic hyperplasia	32.90	13.36	46	62870	18188	110508195
Device malfunction	32.73	13.36	55	62861	25503	110500880
Swollen joint count decreased	32.64	13.36	11	62905	362	110526021
Sleep disorder due to general medical condition, insomnia type	32.19	13.36	10	62906	105633	110420750
Synovial cyst	32.12	13.36	36	62880	11394	110514989
Nephrogenic anaemia	31.91	13.36	24	62892	4553	110521830
Gait inability	31.88	13.36	19	62897	136357	110390026
Total lung capacity increased	31.70	13.36	25	62891	5087	110521296
Haemoptysis	31.68	13.36	101	62815	71253	110455130
Lactic acidosis	31.67	13.36	7	62909	92804	110433579
Epilepsy	31.42	13.36	9	62907	100200	110426183
Synovial disorder	30.89	13.36	20	62896	2987	110523396
Arthralgia	30.77	13.36	618	62298	779014	109747369
Constipation	30.74	13.36	325	62591	357461	110168922
Heart rate increased	30.52	13.36	162	62754	143672	110382711
Echocardiogram abnormal	30.50	13.36	19	62897	2655	110523728
Dry eye	30.49	13.36	85	62831	55708	110470675
Electrocardiogram QT prolonged	30.30	13.36	12	62904	108948	110417435
Hyperkalaemia	30.26	13.36	20	62896	135776	110390607
Lung diffusion test decreased	30.18	13.36	16	62900	1649	110524734
Stiff person syndrome	29.95	13.36	12	62904	648	110525735
Alanine aminotransferase increased	29.93	13.36	193	62723	183580	110342803
Renal impairment	29.83	13.36	38	62878	188407	110337976
Suicide attempt	29.40	13.36	11	62905	103383	110423000
Tremor	29.11	13.36	206	62710	202026	110324357
Drug tolerance decreased	28.50	13.36	54	62862	27486	110498897
Heart rate irregular	28.08	13.36	61	62855	34213	110492170
Wound infection	27.87	13.36	10	62906	96455	110429928
Feeling jittery	27.85	13.36	38	62878	14684	110511699
SAPHO syndrome	27.63	13.36	11	62905	584	110525799
Blood pressure diastolic increased	27.52	13.36	43	62873	18764	110507619
Cardiac failure	27.52	13.36	40	62876	187586	110338797
Hypoglycaemia	27.39	13.36	16	62900	116088	110410295
Blood pressure increased	27.23	13.36	245	62671	258128	110268255
Cushingoid	26.47	13.36	33	62883	11679	110514704
Intentional overdose	26.31	13.36	22	62894	132479	110393904
Grip strength decreased	25.50	13.36	7	62909	80167	110446216
Nasal congestion	25.33	13.36	117	62799	98165	110428218
Poor venous access	25.27	13.36	48	62868	24474	110501909
Death	25.23	13.36	265	62651	698604	109827779
Pulmonary fibrosis	25.22	13.36	120	62796	101922	110424461
Testicular mass	25.20	13.36	7	62909	118	110526265
Bone hypertrophy	25.08	13.36	11	62905	746	110525637
International normalised ratio increased	25.06	13.36	9	62907	86763	110439620
Obesity	24.84	13.36	17	62899	113334	110413049
Therapeutic reaction time decreased	24.82	13.36	22	62894	5257	110521126
Liver function test increased	24.77	13.36	108	62808	88440	110437943
Orthostatic hypertension	24.76	13.36	12	62904	1023	110525360
Renal neoplasm	24.71	13.36	16	62900	2390	110523993
Central obesity	24.58	13.36	15	62901	2021	110524362
Gamma-glutamyltransferase increased	24.53	13.36	3	62913	61306	110465077
Drug ineffective for unapproved indication	24.50	13.36	14	62902	102824	110423559
Peripheral swelling	24.25	13.36	343	62573	403691	110122692
Malignant neoplasm progression	23.89	13.36	39	62877	174528	110351855
Pneumococcal infection	23.50	13.36	14	62902	1805	110524578
Serotonin syndrome	23.41	13.36	3	62913	59150	110467233
Device dislocation	23.26	13.36	54	62862	31650	110494733
Injection site oedema	23.26	13.36	14	62902	1840	110524543
Pharyngitis streptococcal	23.22	13.36	33	62883	13244	110513139
Joint effusion	22.89	13.36	42	62874	20863	110505520
General physical health deterioration	22.77	13.36	354	62562	424941	110101442
Respiration abnormal	22.75	13.36	28	62888	9781	110516602
Drug specific antibody present	22.74	13.36	26	62890	8408	110517975
Klebsiella bacteraemia	22.31	13.36	20	62896	4849	110521534
Hepatic enzyme decreased	22.13	13.36	11	62905	991	110525392
Pulmonary thrombosis	22.13	13.36	33	62883	13830	110512553
Urine odour abnormal	21.95	13.36	24	62892	7391	110518992
Red blood cell sedimentation rate decreased	21.89	13.36	12	62904	1322	110525061
Mental status changes	21.81	13.36	8	62908	76114	110450269
Hypertensive nephropathy	21.76	13.36	11	62905	1027	110525356
Flail chest	21.72	13.36	6	62910	99	110526284
Drug-induced liver injury	21.40	13.36	22	62894	120045	110406338
Unresponsive to stimuli	21.39	13.36	5	62911	63785	110462598
Hypokalaemia	21.22	13.36	45	62871	182403	110343980
Blepharospasm	21.19	13.36	3	62913	54848	110471535
Peak expiratory flow rate abnormal	21.13	13.36	6	62910	110	110526273
Incorrect product administration duration	20.97	13.36	40	62876	20458	110505925
Occupational exposure to product	20.90	13.36	10	62906	829	110525554
Oral herpes	20.74	13.36	56	62860	36024	110490359
Respiratory arrest	20.71	13.36	4	62912	58295	110468088
Facet joint syndrome	20.59	13.36	15	62901	96813	110429570
Lung perforation	20.50	13.36	6	62910	123	110526260
Impaired work ability	20.49	13.36	46	62870	26373	110500010
Agranulocytosis	20.39	13.36	5	62911	61755	110464628
Injection site warmth	20.38	13.36	36	62880	17369	110509014
Medication error	20.30	13.36	18	62898	105348	110421035
Respiratory symptom	20.26	13.36	33	62883	14912	110511471
Atelectasis	20.13	13.36	56	62860	36656	110489727
Hypoaldosteronism	19.85	13.36	9	62907	660	110525723
Patella fracture	19.82	13.36	14	62902	2412	110523971
Drug resistance	19.75	13.36	4	62912	56370	110470013
Thoracic operation	19.66	13.36	7	62909	272	110526111
Renal pain	19.58	13.36	26	62890	9791	110516592
AST/ALT ratio abnormal	19.49	13.36	6	62910	147	110526236
Breath sounds abnormal	19.45	13.36	44	62872	25360	110501023
Metabolic acidosis	19.27	13.36	17	62899	99727	110426656
Osteomyelitis	19.25	13.36	55	62861	36545	110489838
Generalised tonic-clonic seizure	18.91	13.36	4	62912	54676	110471707
Gastrointestinal motility disorder	18.89	13.36	22	62894	7254	110519129
Abdominal pain upper	18.83	13.36	291	62625	348820	110177563
Hypotension	18.73	13.36	199	62717	523650	110002733
Pain	18.65	13.36	691	62225	954264	109572119
Taste disorder	18.51	13.36	7	62909	65380	110461003
Bone marrow failure	18.50	13.36	5	62911	57843	110468540
Melaena	18.43	13.36	8	62908	68749	110457634
Night sweats	18.27	13.36	30	62886	133953	110392430
Pneumonia aspiration	18.04	13.36	12	62904	81221	110445162
Photophobia	17.94	13.36	43	62873	25728	110500655
Blood alkaline phosphatase increased	17.86	13.36	9	62907	70926	110455457
Restlessness	17.73	13.36	5	62911	56254	110470129
Forced vital capacity decreased	17.57	13.36	12	62904	1958	110524425
Accidental overdose	17.50	13.36	4	62912	51830	110474553
Pulmonary toxicity	17.38	13.36	34	62882	17712	110508671
Lower respiratory tract infection	17.33	13.36	213	62703	242893	110283490
Back pain	17.33	13.36	302	62614	370694	110155689
Chromaturia	17.31	13.36	46	62870	29314	110497069
Pulmonary function test decreased	17.29	13.36	23	62893	8677	110517706
Red blood cell sedimentation rate increased	17.16	13.36	89	62827	78213	110448170
Blood immunoglobulin E decreased	17.11	13.36	6	62910	223	110526160
Chronic kidney disease-mineral and bone disorder	17.11	13.36	8	62908	630	110525753
Neuropathy peripheral	17.10	13.36	49	62867	179228	110347155
Hyperglycaemia	17.05	13.36	14	62902	85076	110441307
Bladder disorder	17.05	13.36	26	62890	11111	110515272
Airway remodelling	16.93	13.36	9	62907	933	110525450
Hepatic failure	16.89	13.36	9	62907	68730	110457653
Syncope	16.76	13.36	59	62857	202477	110323906
Nausea	16.76	13.36	861	62055	1234829	109291554
Gastrointestinal haemorrhage	16.71	13.36	44	62872	165474	110360909
Pyrexia	16.57	13.36	387	62529	897878	109628505
White coat hypertension	16.57	13.36	10	62906	1321	110525062
Flank pain	16.54	13.36	39	62877	23091	110503292
Productive cough	16.19	13.36	116	62800	114189	110412194
Bradycardia	15.96	13.36	41	62875	155476	110370907
Injection site extravasation	15.93	13.36	24	62892	10145	110516238
Treatment noncompliance	15.92	13.36	11	62905	72979	110453404
Cardiovascular disorder	15.86	13.36	38	62878	22722	110503661
Deep vein thrombosis	15.85	13.36	35	62881	139852	110386531
Erythema of eyelid	15.84	13.36	15	62901	3900	110522483
Heart rate abnormal	15.73	13.36	20	62896	7218	110519165
Defaecation urgency	15.68	13.36	22	62894	8725	110517658
Overdose	15.65	13.36	74	62842	233720	110292663
Inappropriate schedule of product administration	15.65	13.36	181	62735	203456	110322927
Cerebral infarction	15.62	13.36	5	62911	51833	110474550
Acute respiratory failure	15.56	13.36	12	62904	75248	110451135
Hepatitis	15.49	13.36	17	62899	90037	110436346
Conjunctival haemorrhage	15.49	13.36	19	62897	6614	110519769
Autoimmune disorder	15.48	13.36	9	62907	65474	110460909
Eye irritation	15.44	13.36	48	62868	33404	110492979
Leukopenia	15.44	13.36	39	62877	148752	110377631
Hepatic cytolysis	15.41	13.36	6	62910	55047	110471336
Cardiac failure congestive	15.35	13.36	40	62876	150960	110375423
Cerebral haemorrhage	15.25	13.36	9	62907	64959	110461424
Klebsiella test positive	15.25	13.36	12	62904	2434	110523949
Eosinophilia	15.12	13.36	7	62909	57929	110468454
Knee deformity	15.09	13.36	10	62906	1553	110524830
Septic shock	15.06	13.36	43	62873	157485	110368898
Pneumocystis jirovecii pneumonia	15.04	13.36	3	62913	42732	110483651
Contusion	14.96	13.36	75	62841	233286	110293097
Keratomileusis	14.91	13.36	5	62911	162	110526221
Renal mass	14.84	13.36	14	62902	3621	110522762
Abnormal faeces	14.76	13.36	22	62894	9214	110517169
Pancreatitis acute	14.65	13.36	8	62908	60266	110466117
Underdose	14.65	13.36	9	62907	63545	110462838
Toxic epidermal necrolysis	14.58	13.36	7	62909	56720	110469663
Carcinoid tumour	14.54	13.36	7	62909	588	110525795
Haematocrit decreased	14.37	13.36	10	62906	66107	110460276
Device dependence	14.37	13.36	4	62912	68	110526315
Eye ulcer	14.23	13.36	6	62910	369	110526014
Muscle strain	14.20	13.36	24	62892	11178	110515205
Stress at work	14.07	13.36	9	62907	1316	110525067
Hyperparathyroidism secondary	14.02	13.36	13	62903	3291	110523092
Intentional product misuse	13.98	13.36	126	62790	132778	110393605
Sinus tachycardia	13.94	13.36	4	62912	44489	110481894
Eye pain	13.93	13.36	61	62855	50038	110476345
Femur fracture	13.93	13.36	4	62912	44465	110481918
Blood lactate dehydrogenase increased	13.86	13.36	4	62912	44330	110482053
Skin cancer	13.83	13.36	31	62885	17753	110508630
Blood urea increased	13.79	13.36	7	62909	54950	110471433
Adjustment disorder with depressed mood	13.64	13.36	4	62912	43879	110482504
Renal haemangioma	13.59	13.36	3	62913	18	110526365
Appendix disorder	13.48	13.36	10	62906	1858	110524525

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BC06	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors
FDA MoA	N0000000147	Proton Pump Inhibitors
FDA EPC	N0000175525	Proton Pump Inhibitor
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D054328	Proton Pump Inhibitors

Related Drugs by ATC class:

A02BC Proton pump inhibitors 8 drugs

dexrabeprazole esomeprazole ilaprazole lansoprazole omeprazole pantoprazole rabeprazole vonoprazan

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Erosive esophagitis	indication	40719004
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Maintenance of Healing Erosive Esophagitis	indication
Duodenal ulcer disease	off-label use	51868009	DOID:1724
Zollinger-Ellison syndrome	off-label use	53132006	DOID:0050782
Gastric ulcer	off-label use	397825006	DOID:10808
Duodenal Ulcer due to H. Pylori	off-label use
Maintenance of Healing Duodenal Ulcer	off-label use
NSAID-Induced Gastric Ulcer	off-label use
Prevention of NSAID-Induced Gastric Ulcer	off-label use
Pathological Gastric Hypersecretory Condition	off-label use
Osteoporosis	contraindication	64859006	DOID:11476
Fracture of bone	contraindication	125605004
Hypomagnesemia	contraindication	190855004
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.23	acidic
pKa2	3.35	Basic
pKa3	2.72	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	9233103	March 5, 2032	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	9233103	March 5, 2032	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Potassium-transporting ATPase	Transporter	P20648 P51164	ATP4A_HUMAN ATP4B_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Cytosolic endo-beta-N-acetylglucosaminidase	Enzyme	Q8NFI3	ENASE_HUMAN		IC50	4.60	CHEMBL
Sterile alpha and TIR motif-containing protein 1	Enzyme	Q6SZW1	SARM1_HUMAN		IC50	5.48	CHEMBL

External reference:

ID	Source
4028570	VUID
N0000189452	NUI
D08903	KEGG_DRUG
313640-86-7	SECONDARY_CAS_RN
4028570	VANDF
C2348248	UMLSCUI
CHEMBL1201863	ChEMBL_ID
D064748	MESH_DESCRIPTOR_UI
DB05351	DRUGBANK_ID
5487	IUPHAR_LIGAND_ID
8524	INN_ID
UYE4T5I70X	UNII
9578005	PUBCHEM_CID
2673463	RXNORM
160770	MMSL
172755	MMSL
26184	MMSL
356045	MMSL
d07395	MMSL
012953	NDDF
441863009	SNOMEDCT_US
442540007	SNOMEDCT_US
CHEBI:135931	CHEBI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2085	CAPSULE, DELAYED RELEASE PELLETS	30 mg	ORAL	ANDA	30 sections
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2086	CAPSULE, DELAYED RELEASE PELLETS	60 mg	ORAL	ANDA	30 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	24979-001	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	32 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	24979-002	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	32 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	24979-703	CAPSULE, DELAYED RELEASE	30 mg	ORAL	NDA AUTHORIZED GENERIC	32 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	24979-704	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA AUTHORIZED GENERIC	32 sections
Dexlansoprazole	Human Prescription Drug Label	1	46708-823	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	27 sections
Dexlansoprazole	Human Prescription Drug Label	1	46708-824	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	27 sections
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-147	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	27 sections
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-148	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	27 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5944	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6514	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	32 sections
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7451	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	27 sections
Dexlansoprazoledelayed release	HUMAN PRESCRIPTION DRUG LABEL	1	51407-746	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	32 sections
Dexlansoprazoledelayed release	HUMAN PRESCRIPTION DRUG LABEL	1	51407-747	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	32 sections
Kapidex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5998	CAPSULE, DELAYED RELEASE	30 mg	ORAL	NDA	16 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6152	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA	31 sections
Dexlansoprazole	Human Prescription Drug Label	1	62332-823	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	27 sections
Dexlansoprazole	Human Prescription Drug Label	1	62332-824	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	27 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	64764-171	CAPSULE, DELAYED RELEASE	30 mg	ORAL	NDA	32 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	64764-175	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA	32 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	71335-3071	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	31 sections
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2214	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	28 sections
Dexlansoprazole delayed release	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2239	CAPSULE, DELAYED RELEASE	60 mg	ORAL	ANDA	31 sections
Dexlansoprazole	HUMAN PRESCRIPTION DRUG LABEL	1	72162-2244	CAPSULE, DELAYED RELEASE	30 mg	ORAL	ANDA	28 sections

Ask DrugCentral

dexlansoprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: